The FDA has granted accelerated approval to Avmapki (avutometinib) plus Fakzynja (defactinib) for the treatment of KRAS-mutated, recurrent low-grade serous ovarian cancer.

GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, ...

The Food and Drug Administration (FDA) has granted accelerated approval to Avmapki ™ (avutometinib) plus Fakzynja ™ (defactinib) for the treatment of adult patients with KRAS -mutated recurrent ...

Migraine is a neurological disorder that can worsen in some people including menopausal women A gynaecologist explains why it ...

Many of us deal with anxiety and when you're bringing a baby into this world, it can be even more pronounced. The problem ...

Somatic yoga borrows principles from somatic therapy to help people form a bridge between their body and mind. Learn about ...

US FDA approves Verastem’s Avmapki Fakzynja combo therapy to treat patients with KRAS-mutated recurrent low-grade serous ovarian cancer: Boston Saturday, May 10, 2025, 13:00 Hrs ...

GLP-1 medications like Ozempic, Wegovy and Mounjaro have gone from obscure diabetes treatments to front-page news thanks to ...

In 2014, the researchers of the recent PLoS One study published a meta-analysis revealing that physical exercise had a ...

The filmmaker’s candid post opens a conversation about health, stigma, and promising advances in diabetes and weight ...

Faced with a medical establishment that doesn’t serve them, a volatile political environment, and a technological revolution, ...